• CytoDyn Inc., of Lake Oswego, Ore., said it and Drexel University entered a deal with contract development and manufacturing firm Ajinomoto Althea Inc. to formulate CytoDyn's PRO 140 bulk drug substance through a fill-and-finish process for clinical-ready vials to advance two National Institutes of Health (NIH)-funded Phase IIb studies.